Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intraocular Pressure | 5 | 2026 | 65 | 0.740 |
Why?
|
| Tomography, Optical Coherence | 5 | 2025 | 114 | 0.710 |
Why?
|
| Glaucoma | 4 | 2026 | 39 | 0.570 |
Why?
|
| Visual Fields | 5 | 2025 | 41 | 0.560 |
Why?
|
| Glaucoma, Open-Angle | 4 | 2025 | 26 | 0.540 |
Why?
|
| Optic Disk | 4 | 2025 | 23 | 0.540 |
Why?
|
| Visual Field Tests | 4 | 2025 | 16 | 0.510 |
Why?
|
| Retinal Vessels | 2 | 2025 | 20 | 0.430 |
Why?
|
| Retinal Ganglion Cells | 4 | 2025 | 15 | 0.410 |
Why?
|
| Ocular Hypertension | 3 | 2025 | 10 | 0.330 |
Why?
|
| Nerve Fibers | 3 | 2025 | 12 | 0.330 |
Why?
|
| Optic Nerve Diseases | 2 | 2024 | 21 | 0.260 |
Why?
|
| Vision Disorders | 2 | 2024 | 61 | 0.260 |
Why?
|
| Trabeculectomy | 1 | 2026 | 11 | 0.240 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2026 | 8 | 0.240 |
Why?
|
| Macular Edema | 1 | 2026 | 31 | 0.230 |
Why?
|
| Macula Lutea | 1 | 2025 | 5 | 0.230 |
Why?
|
| Metformin | 1 | 2026 | 84 | 0.220 |
Why?
|
| Oximetry | 1 | 2024 | 65 | 0.210 |
Why?
|
| Hypoglycemic Agents | 1 | 2026 | 227 | 0.210 |
Why?
|
| Pterygium | 2 | 2011 | 3 | 0.180 |
Why?
|
| Conjunctiva | 2 | 2011 | 14 | 0.180 |
Why?
|
| Disease Progression | 1 | 2024 | 880 | 0.170 |
Why?
|
| Smoking | 1 | 2024 | 526 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2026 | 591 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2026 | 2318 | 0.150 |
Why?
|
| Postoperative Complications | 1 | 2026 | 1099 | 0.150 |
Why?
|
| Middle Aged | 9 | 2026 | 13419 | 0.120 |
Why?
|
| Aged | 6 | 2026 | 10429 | 0.110 |
Why?
|
| Fluorescein Angiography | 2 | 2025 | 36 | 0.110 |
Why?
|
| Incidence | 2 | 2026 | 1085 | 0.090 |
Why?
|
| Risk Factors | 3 | 2026 | 4017 | 0.090 |
Why?
|
| Memantine | 1 | 2011 | 6 | 0.090 |
Why?
|
| Alkylating Agents | 1 | 2011 | 22 | 0.090 |
Why?
|
| Mitomycin | 1 | 2011 | 19 | 0.090 |
Why?
|
| Limbus Corneae | 1 | 2011 | 8 | 0.090 |
Why?
|
| Optic Neuritis | 1 | 2011 | 21 | 0.090 |
Why?
|
| Anterior Eye Segment | 1 | 2011 | 5 | 0.090 |
Why?
|
| Axons | 1 | 2011 | 44 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2011 | 46 | 0.090 |
Why?
|
| Male | 9 | 2026 | 27435 | 0.090 |
Why?
|
| Photorefractive Keratectomy | 1 | 2011 | 2 | 0.090 |
Why?
|
| Eye Pain | 1 | 2011 | 5 | 0.090 |
Why?
|
| Diclofenac | 1 | 2011 | 10 | 0.090 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2011 | 79 | 0.090 |
Why?
|
| Female | 9 | 2026 | 28782 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 124 | 0.080 |
Why?
|
| Pain, Postoperative | 1 | 2011 | 169 | 0.080 |
Why?
|
| Visual Acuity | 2 | 2026 | 155 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1723 | 0.070 |
Why?
|
| Humans | 10 | 2026 | 53230 | 0.070 |
Why?
|
| Propensity Score | 1 | 2026 | 170 | 0.060 |
Why?
|
| Retina | 1 | 2024 | 76 | 0.050 |
Why?
|
| Oxygen | 1 | 2024 | 338 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 774 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 1049 | 0.040 |
Why?
|
| Transplantation, Autologous | 2 | 2011 | 488 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2011 | 729 | 0.040 |
Why?
|
| Young Adult | 3 | 2011 | 4511 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2011 | 5595 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2011 | 2411 | 0.030 |
Why?
|
| Adult | 4 | 2011 | 14534 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2026 | 6819 | 0.030 |
Why?
|
| Contrast Sensitivity | 1 | 2011 | 6 | 0.020 |
Why?
|
| Evoked Potentials, Visual | 1 | 2011 | 29 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 122 | 0.020 |
Why?
|
| Myopia | 1 | 2011 | 9 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2011 | 62 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 259 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 694 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 2991 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 6907 | 0.010 |
Why?
|